LYEL - Lyell Immunopharma Inc
IEX Last Trade
1.455
-0.005 -0.344%
Share volume: 1,025,531
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.46
-0.01
-0.34%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-08 | 2023-02-28 | 2023-05-04 | 2023-08-08 | 2023-11-07 | 2024-02-28 | 2024-05-06 | |
| Assets | |||||||||
| Total Assets | 1.022 B | 977.269 M | 937.561 M | 880.450 M | 835.354 M | 794.989 M | 750.029 M | 694.220 M | |
| Current Assets | 666.778 M | 659.745 M | 651.295 M | 624.398 M | 606.410 M | 586.854 M | 554.686 M | 534.165 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 11.214 M | 11.613 M | 11.143 M | 11.629 M | 10.662 M | 11.423 M | 8.463 M | 7.865 M | |
| Short Term Investments | 11.214 M | 11.613 M | 11.143 M | 11.629 M | 10.662 M | 11.423 M | 8.463 M | 7.865 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 655.564 M | 648.132 M | 640.152 M | 612.769 M | 595.748 M | 575.431 M | 546.223 M | 526.300 M | |
| Total Non-current Assets | 354.896 M | 317.524 M | 286.266 M | 256.052 M | 228.944 M | 208.135 M | 195.343 M | 160.055 M | |
| Property Plant Equipment | 127.559 M | 125.727 M | 123.023 M | 118.600 M | 113.677 M | 108.096 M | 102.654 M | 97.836 M | |
| Other Assets | 48.619 M | 46.998 M | 47.922 M | 46.992 M | 46.032 M | 45.026 M | 43.898 M | 42.933 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 1.022 B | 977.269 M | 937.561 M | 880.450 M | 835.354 M | 794.989 M | 750.029 M | 694.220 M | |
| Total liabilities | 153.632 M | 157.243 M | 104.309 M | 96.624 M | 98.499 M | 97.416 M | 95.077 M | 91.063 M | |
| Total current liabilities | 50.291 M | 51.217 M | 37.028 M | 30.797 M | 34.390 M | 35.064 M | 34.519 M | 32.353 M | |
| Accounts Payable | 4.247 M | 4.795 M | 3.917 M | 5.733 M | 5.805 M | 4.365 M | 4.817 M | 4.895 M | |
| Other liabilities | 37.267 M | 41.390 M | 4.113 M | 4.001 M | 3.888 M | 3.776 M | 3.664 M | 3.551 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 66.074 M | 64.636 M | 63.168 M | 61.826 M | 60.221 M | 58.576 M | 56.894 M | 55.159 M | |
| Other liabilities | 37.267 M | 41.390 M | 4.113 M | 4.001 M | 3.888 M | 3.776 M | 3.664 M | 3.551 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 868.042 M | 820.026 M | 833.252 M | 783.826 M | 736.855 M | 697.573 M | 654.952 M | 603.157 M | |
| Common stock | 246.312 M | 248.320 M | 249.510 M | 249.591 M | 250.204 M | 251.318 M | 252.819 M | 254.252 M | |
| Retained earnings | -688.829 M | -759.083 M | -767.480 M | -834.439 M | -898.329 M | -949.182 M | -1.002 B | -1.063 B |